

Performance in Initiating and Delivering (PID) Clinical Research
UCLH Performance in Approving and Recruiting to Research
July 2019

Since July 2012, providers of NHS services have been providing data on performance in initiating and delivering clinical research. Data for studies which have received NHS approval (known as Decision to Deliver) in the previous 12 months is submitted quarterly to the National Institute for Health Research (NIHR). Below is a summary of performance submitted by UCLH in Quarter 1 (2019/20) for studies where UCLH was selected as a site over the past year.

Providers are asked to publish details of the length of time taken to approve clinical trials from the point from Date Site Selected to recruitment of the first participant. This period is known as the initiation stage and the NIHR has assigned a benchmark target of 70 days.

Providers also submit information on those Commercially Sponsored Trials, which have closed to recruitment in the year and whether the trial has achieved its anticipated total recruitment target. The period between recruitment of the first participant and reaching the total recruitment target is known as the delivery stage. Each quarter, UCLH will update this information with the most recent studies. The data is correct as of end of June 2019.

For Further information on PID reporting, please visit the NIHR pages at:

<https://www.nihr.ac.uk/documents/performance-in-initiating-and-delivering-guidelines/19932>

Initiating Clinical Research – HRA Approval

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Participant Recruited	Benchmark Met	Reasons for delay correspond to:
1	17/SC/0090	215068	c-TRAK TN	19/10/2017	20/07/2018	22/07/2017		24/08/2018	24/08/2018		No	Neither
2	17/LO/0935	222593	Changes in Structure & Blood flow of GBM in response to CRT	02/08/2017	12/11/2018	02/08/2018		28/11/2018	28/11/2018		No	NHS Provider
3	17/SS/0105	209066	TEMPO-2	07/03/2018	23/10/2018			16/11/2018	16/11/2018		No	Sponsor
4	18/EM/0119	244650	Chemotherapy+/- MK-3475 in TKI-resistant EGFR-mutated Tumors in NSCLC	13/02/2018	30/08/2018	06/07/2018	28/08/2018	03/09/2018	03/09/2018	10/12/2018	No	Neither
5	17/SC/0536	216069	COPELIA	20/10/2017	31/07/2018	04/12/2017	05/09/2018	06/09/2018	06/09/2018	16/10/2018	No	Neither
6	18/YH/0329	236786	PEACOCC	30/07/2018	20/11/2018	16/10/2018	11/12/2018	21/12/2018	18/02/2019	04/03/2019	No	Neither
7	18/LO/1382	244284	Vast Improvements in Oesophageal ImagiNg	18/07/2018	18/09/2018	18/09/2018		16/10/2018	16/10/2018	05/02/2019	No	Neither
8	18/EM/0148	236593	Durvalumab + BCG in NMIBC	24/05/2018	15/01/2019	16/07/2018		16/01/2019	16/01/2019	27/03/2019	No	Neither
9	18/LO/1918	252958	A Phase 1 Study of BIVV009 in Patients with Chronic ITP (BIVV009-201)	13/08/2018	08/03/2019	08/03/2019		25/03/2019	25/03/2019		No	Neither

10	18/SW/0247	248334	BEGONIA - Phase II study of oncology combinations in 1L Stage IV TNBC.	12/09/2018	12/04/2019			12/04/2019	18/06/2019		No	Neither
11	17/SC/0615	233555	VIOLETTE	07/03/2018	09/07/2018	05/01/2018	19/07/2018	03/08/2018	06/12/2018	13/12/2018	No	Neither
12	19/LO/0101	258992	Cancer Peptide Vaccine	17/12/2018	22/01/2019	02/05/2019	22/01/2019	22/01/2019	05/06/2019		No	Sponsor
13	12/LO/0082	211212	MS-OPT Study: Simvastatin in Secondary Progressive Multiple Sclerosis	16/03/2018	20/02/2019	31/01/2018		27/03/2019	27/03/2019	19/06/2019	No	NHS Provider
14	18/LO/0079	232937	LJPC-401 for iron overload in adults with TDT	09/02/2018	06/07/2018	23/03/2018		11/07/2018	11/07/2018		No	Neither
15	18/EE/0176	236637	Daratumumab in paediatric and young adults with ALL/LL	22/12/2017	01/11/2018	13/08/2018		01/11/2018	01/11/2018		No	Neither
16	18/LO/1141	241087	Minifast - Obs	18/01/2018	25/07/2018	24/07/2018		25/07/2018	09/08/2018		No	Sponsor
17	18/LO/1471	248645	AUDIBLE-S	01/08/2018	27/02/2019	14/11/2018	05/03/2019	11/03/2019	11/03/2019		No	Sponsor
18	18/LO/1598	234799	Feasibility Pilot of a Health Behaviour Change Intervention for TYACS	22/10/2018	14/11/2018	22/10/2018		16/11/2018	16/11/2018		No	Sponsor
19	18/EM/0255	237130	Project on EUS- BD	29/10/2018	07/02/2019	09/10/2018		20/02/2019	20/02/2019		No	Neither
20	18/EE/0330	249125	EASE SBS1 Efficacy And Safety Evaluation of Glepaglutide in SBS	21/12/2018	11/02/2019	11/12/2018	21/02/2019	25/04/2019	25/04/2019	16/05/2019	No	NHS Provider

21	18/SC/0412	250170	Pembrolizumab/Placebo Plus Trastuzumab Plus Chemo in HER2+ Gastric/GEJ	25/06/2018	12/10/2018	19/10/2018	31/10/2018	15/11/2018	15/11/2018	20/12/2018	No	Neither
22	18/LO/1435	247443	CHIRON ATX-NS-001 - ATL001 for the Treatment of Non-Small Cell Lung Cancer	01/02/2019	01/03/2019	15/02/2019		17/05/2019	17/05/2019		No	NHS Provider
23	18/LO/1407	243999	EndoRotor for Refractory BE	05/03/2018	24/10/2018	17/10/2018	06/12/2018	07/12/2018	11/01/2019	28/01/2019	No	Neither
24	18/NI/0084	239210	Phase 3 trial to evaluate subcutaneous elamipretide injections for PMM	02/07/2018	03/07/2018	26/06/2018	08/10/2018	08/10/2018	08/10/2018	25/10/2018	No	Sponsor
25	16/EM/0322	202096	Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST)	24/11/2017	17/07/2018	18/08/2017	17/07/2018	17/07/2018	17/07/2018	29/04/2019	No	Neither
26	18/LO/0951	241359	AB-PSP-001	10/04/2018	06/08/2018	19/07/2018	25/09/2018	26/09/2018	26/09/2018	31/10/2018	No	Sponsor
27	17/WA/0417	237540	Study to evaluate the safety of crushed defasirox in paediatrics V00	01/02/2018	17/10/2018			04/03/2019	04/03/2019	23/05/2019	No	NHS Provider
28	18/LO/1187	240011	ATHENA - a first line ovarian cancer maintenance trial.	02/05/2018	20/09/2018	11/09/2018		13/11/2018	13/11/2018	30/04/2019	No	Neither

29	18/WS/0137	247036	VISION Study of 177Lu-PSMA-617 in the treatment of PSMA-Positive mCRPC	01/06/2018	19/12/2018	10/09/2018	14/11/2018	21/03/2019	04/04/2019		No	Neither
30	18/EM/0153	240773	AG-348-C-006 in Not Regularly Transfused Subjects with PK Deficiency	27/03/2018	06/12/2018	28/08/2018		11/03/2019	04/04/2019		No	Sponsor
31	18/WM/0022	237623	AG-348 in Regularly Transfused Adult Subjects with PK Deficiency	02/02/2018	09/01/2019	11/04/2018		18/03/2019	18/03/2019		No	Sponsor
32	18/LO/0710	245369	Polar A	09/05/2018	21/12/2018	30/08/2018	31/05/2019	31/05/2019	31/05/2019		No	Sponsor
33	19/LO/0109	257158	BN40955 OLE study to evaluate the safety & tolerability of RO7234292	19/12/2018	16/01/2019	07/03/2019	24/05/2019	24/05/2019	24/05/2019	29/05/2019	No	NHS Provider
34	18/EE/0300	236285	PROMPT	26/09/2018	29/10/2018	19/10/2018		30/01/2019	03/06/2019		No	Sponsor
35	18/EE/0282	249797	NP39488 - Phase 1B RO7082859 & Atezolizumab in Non-Hodgkin's Lymphoma	20/06/2018	19/09/2018	29/10/2018	12/12/2018	17/12/2018	17/12/2018	26/02/2019	No	NHS Provider
36	18/NE/0292	252024	SIDEROS-E	06/07/2018	31/10/2018	26/10/2018		15/01/2019	15/01/2019	16/01/2019	No	NHS Provider
37	18/LO/1854	251689	Pembrolizumab/placebo plus chemo as 1L therapy in HER2-Gastric/GEJ	14/09/2018	05/11/2018	18/12/2018	09/01/2019	14/01/2019	18/01/2019	28/05/2019	No	Sponsor

38	18/LO/1313	246934	Ph3 Randomised Double-blind Study of Arimoclomol in Patients with ALS	09/07/2018	26/07/2018	19/11/2018	31/01/2019	31/01/2019	31/01/2019	01/05/2019	No	Both
39	17/LO/0727	217211	Phase 2/3 study in neonates with repeated EEG seizures	27/03/2017	24/09/2018	05/09/2017		14/06/2019	14/06/2019		No	Sponsor
40	18/EE/0280	247599	Trial of Ursodeoxycholic Acid (UDCA) for PD. The 'UP-study'	13/08/2018	12/11/2018	12/11/2018	09/04/2019	10/04/2019	10/04/2019	06/06/2019	No	Sponsor
41	17/LO/0357	202353	Better Conversations with Primary Progressive Aphasia (BCPPA)	02/11/2016	13/02/2019	26/04/2017	27/03/2019	27/03/2019	27/03/2019	03/05/2019	No	Neither
42	18/EM/0079	230431	Vaccination for immune recovery following sepsis:The VACIRISS Trial	12/04/2018	08/08/2018	16/04/2018	11/02/2019	09/10/2018	13/02/2019	04/03/2019	No	Sponsor
43	17/LO/2060	230779	ZUMA-7	13/12/2017	23/07/2018	18/09/2018		13/03/2019	13/03/2019	08/05/2019	No	Both
44	18/LO/1156	239889	ANDROMEDA (54767414AMY3001)	01/03/2018	22/08/2018	05/10/2018	15/01/2019	29/01/2019	29/01/2019	12/02/2019	No	Sponsor
45	18/EE/0005	232671	Effect on HRCT Endpoints to Glucocorticoid in Pulmonary Sarcoidosis	08/08/2017	13/11/2018	19/07/2018	30/01/2019	05/02/2019	05/02/2019		No	Sponsor
46	19/LO/0421	259113	ROZANOLIXIZUMAB in subjects with CIDP	15/02/2019	20/03/2019						No	Sponsor

47	18/LO/0793	241404	RCT: Mako FA TKA vs Mako MA TKA	18/06/2018	15/10/2018	18/06/2018		07/11/2018	07/11/2018	21/12/2018	No	NHS Provider
48	18/LO/0165	224726	POLEM	27/06/2018	16/08/2018	09/05/2018		06/11/2018	06/11/2018		No	Neither
49	18/EE/0095	239387	A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer	04/02/2019	17/04/2019	14/05/2018	12/06/2019	12/06/2019	12/06/2019		No	NHS Provider
50	18/NE/0072	235113	CITADEL-205	28/03/2017	11/07/2018	18/05/2018		30/08/2018	30/08/2018		No	Neither
51	18/SC/0525	238638	IPI-GLIO: Ipilimumab in Recently Diagnosed Glioblastoma	17/10/2018	19/12/2018	05/11/2018		06/03/2019	06/03/2019	29/04/2019	No	NHS Provider
52	18/WA/0309	250252	Improving cognition in people with Progressive Multiple Sclerosis	01/11/2018	20/11/2018	20/11/2018	09/01/2019	09/01/2019	18/03/2019	21/03/2019	No	Sponsor
53	19/SC/0113	241916	Idera 2125-MEL-301	09/11/2018	18/03/2019	24/04/2019					No	NHS Provider
54	18/LO/0106	170254	HYPATIA study	27/02/2018	29/03/2019	09/03/2018					No	NHS Provider
55	18/EM/0112	236871	ALL-RIC	19/07/2018	19/07/2018	12/06/2018	28/09/2018	25/10/2018	01/11/2018	06/03/2019	No	Both
56	18/LO/0687	228293	JCAR017 In Adults With Aggressive B-Cell Non-Hodgkin Lymphoma	09/04/2018	09/07/2018	07/08/2018		30/10/2018	30/10/2018	13/11/2018	No	NHS Provider

57	18/NW/0713	249575	DIONE – Efficacy and Safety of TD-1473 in Crohn’s Disease	27/07/2018	30/01/2019	28/11/2018	22/03/2019	28/03/2019	28/03/2019		No	Both
58	18/LO/2053	251610	AL001-1	06/12/2018	25/01/2019	24/01/2019		29/03/2019	04/04/2019	05/06/2019	No	Sponsor
59	17/LO/0980	219505	HALT - Stereotactic Body Radiotherapy for the treatment of OPD	26/11/2018	12/04/2019	10/07/2017	19/06/2019	19/06/2019	19/06/2019		No	Sponsor
60	18/ES/0136	249697	X-linked Hypophosphatemia (XLH) - Kyowa Kirin - 0978/0008	17/12/2018	18/04/2019	21/12/2018	23/05/2019	30/05/2019	30/05/2019		No	Sponsor
61	19/SC/0021	249552	OPTIMAS Trial	19/12/2018	16/04/2019	04/04/2019	18/06/2019	18/06/2019	18/06/2019		No	Sponsor
62	18/SC/0610	242511	POPPY	12/11/2018	10/01/2019	08/01/2019		04/04/2019	04/04/2019		No	Sponsor
63	19/NE/0031	258311	Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC (KEYNOTE-630)	16/01/2019	04/04/2019	04/03/2019					No	Sponsor
64	18/EE/0352	238983	Biomarker-Directed, Pembrolizumab Based Combination Therapy for Advanced NSCLC	12/10/2018	19/02/2019	14/02/2018		02/05/2019	02/05/2019		No	Sponsor
65	18/EM/0310	239782	C-STICH2 Randomised controlled trial of emergency cerclage	28/11/2018	11/12/2018	16/11/2018		05/04/2019	05/04/2019		No	Sponsor
66	17/LO/1140	223446	Phase II Study of Tipifarnib in non-haematological cancer and HRAS	17/10/2017	23/08/2018	22/09/2017	09/04/2018	09/01/2019	09/01/2019		No	Both

67	18/WS/0099	245374	CPI-0610 with or without ruxolitinib	04/06/2018	02/11/2018	02/07/2018	17/12/2018	04/01/2019	04/01/2019		No	Neither
68	18/WA/0239	243333	DELIVER MS	04/12/2018	22/01/2019	21/12/2018		08/03/2019	08/03/2019	25/06/2019	No	Both
69	17/YH/0436	234886	BP40234: RO6874281 in combination with atezolizumab in solid tumours	06/08/2018	29/08/2018	27/02/2018	13/12/2018	05/01/2019	05/01/2019	04/04/2019	No	Sponsor
70	18/NE/0309	252961	A safety study of REN001 in mitochondrial myopathy	02/10/2018	04/12/2018		02/04/2019	02/04/2019	01/05/2019		No	NHS Provider
71	18/LO/0555	237992	PROTECTOR	03/08/2018	29/01/2019	19/04/2018	28/03/2019	28/03/2019	28/03/2019		No	Sponsor
72	18/LO/0862	241382	RCT: CO THA vs Mako THA	03/05/2018	08/11/2018	04/07/2018		08/11/2018	08/11/2018	05/12/2018	No	NHS Provider
73	18/LO/0434	242324	Fabry disease study to determine the safety and efficacy of lucerastat	19/01/2018	04/04/2019						No	NHS Provider
74	18/LO/0866	224730	PROHIBIT-ICH	15/12/2017	12/09/2018	26/06/2018	12/10/2018	15/10/2018	15/10/2018	22/03/2019	No	Sponsor
75	18/LO/0144	239494	Intra-oral treatment of OLP with Rivelin®-CLO patches	04/12/2017	10/07/2018	17/05/2018	03/08/2018	09/08/2018	09/08/2018	18/09/2018	Yes	N/A
76	18/LO/0021	236581	EACH	10/01/2018	11/07/2018	26/03/2018		16/07/2018	16/07/2018	19/09/2018	Yes	N/A
77	18/LO/1882	253030	Abiraterone Acetate + Prednisone with Abemaciclib or placebo for mCRPC	26/11/2018	02/04/2019	13/02/2019	10/04/2019	10/04/2019	10/04/2019	11/06/2019	Yes	N/A

78	18/LO/1405	63284	Cochleostomy vs Round Window for Hearing Preservation in CI	13/09/2018	01/04/2019	13/09/2018		02/05/2019	02/05/2019	16/05/2019	Yes	N/A
79	19/EM/0034	255895	Padsenovil for Focal Seizures in Adults with Drug-Resistant Epilepsy	25/01/2019	24/04/2019	16/06/2019					N/A	N/A
80	18/SC/0634	233709	STELLAR	05/03/2019	25/04/2019						N/A	N/A
81	19/LO/0579	251741	Sonic Sleeve (v 0.1)	07/05/2019	14/06/2019	05/06/2019		08/07/2019	08/07/2019		N/A	N/A
82	18/LO/1889	250623	TACTI-002 (P015); Keynote-PN798 (Two Active Immunotherapeutics)	17/10/2018	28/05/2019	12/02/2019	04/07/2019	04/07/2019	04/07/2019		N/A	N/A
83	18/LO/1502	246324	CARRIER-trial: S. aureus decolonization in HPN patients	03/05/2018	25/05/2019	17/12/2018	01/07/2019	01/07/2019	01/07/2019		N/A	N/A
84	18/EM/0085	208868	HOVON 127 BL	27/07/2018	20/05/2019	12/06/2018					N/A	N/A
85	19/EM/0020	252705	TAPER	30/04/2019	31/05/2019						N/A	N/A
86	19/LO/1024	263894	Pembrolizumab ± SBRT in Medically Inoperable Stage I/IIA NSCLC	17/12/2018	04/06/2019						N/A	N/A
87	19/LO/0841	262121	ROZANOLIXIZUMAB in subjects with CIDP Open-Label Extension	03/05/2019	12/06/2019						N/A	N/A
88	19/NW/0006	254693	BGB-3111-214-A Phase 2 OLE Study of BGB-3111 in patients with MZL	14/12/2018	02/05/2019		04/06/2019	27/06/2019	05/07/2019		N/A	N/A

89	18/LO/0569	233097	The HOME Study	08/05/2018	25/04/2019	04/07/2018		25/04/2019	25/04/2019		N/A	N/A
90	17/LO/2025	229356	ROLo	03/09/2018	12/06/2019	26/04/2018					N/A	N/A
91	19/LO/0272	255069	An RCT of ACT for people with MND	30/01/2019	17/06/2019						N/A	N/A
92	19/LO/0870	252908	ToTem	15/02/2019	18/06/2019						N/A	N/A
93	18/LO/0266	235855	Novel multimodality imaging for navigation in skull base surgery	09/04/2018	15/04/2019	09/04/2018	17/04/2019	17/04/2019	17/04/2019	03/06/2019	Yes	N/A
94	18/LO/2137	244929	PembroWM	05/04/2019	19/06/2019	19/03/2019					N/A	N/A
95	19/LO/0819	263201	A Phase 1b Open Label Study of RENO01 in McArdle Disease	26/04/2019	27/06/2019	27/06/2019					N/A	N/A
96	19/EE/0201	264655	OLYMPUS	28/06/2019	28/06/2019						N/A	N/A
97	18/LO/0227	228539	A feasibility study of ACT for people with MND (Phase 1) v1	23/08/2017	11/07/2018	16/01/2018		27/07/2018	27/07/2018	14/09/2018	Yes	N/A
98	18/EE/0197	246434	Phase 2 study of the Safety and Efficacy of ADCT-402 on DLBCL Patients	12/06/2018	06/11/2018	10/08/2018	25/10/2018	18/12/2018	18/12/2018	24/12/2018	Yes	N/A
99	18/LO/0789	238844	FLICC II	09/06/2017	14/08/2018	14/08/2018	09/10/2018	09/10/2018	09/10/2018	12/10/2018	Yes	N/A
100	18/LO/1148	240856	THRIVEN90	31/07/2018	22/08/2018	31/07/2018		19/09/2018	19/09/2018	25/10/2018	Yes	N/A
101	18/LO/0030	225990	BARI-OPTIMISE Version 1	28/09/2017	16/07/2018	05/04/2018	26/07/2018	31/07/2018	31/07/2018	19/10/2018	Yes	N/A

102	18/LO/0995	244737	Phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer	14/12/2017	21/09/2018	20/09/2018	25/09/2018	24/10/2018	24/10/2018	27/11/2018	Yes	N/A
103	18/LO/0926	241393	RCT: Inflammatory response CO TKA vs Mako TKA	20/10/2017	07/11/2018	02/05/2018		07/11/2018	07/11/2018	07/12/2018	Yes	N/A
104	18/EM/0364	254750	4433: NNC0174-0833 for weight management	03/09/2018	11/01/2019			22/02/2019	22/02/2019	01/03/2019	Yes	N/A
105	18/ES/0042	241253	STARTUP	19/04/2018	22/10/2018	04/07/2018		31/10/2018	31/10/2018	14/12/2018	Yes	N/A
106	18/SC/0250	243935	Mental health in children with epilepsy trial (MICE)	24/04/2018	05/10/2018	21/05/2018	23/11/2018	24/10/2018	22/11/2018	03/12/2018	Yes	N/A
107	18/LO/2136	251414	BN40423 Generation HD 1	11/12/2018	22/05/2019	22/02/2019					N/A	N/A
108	18/LO/0858	241447	MX39795: A phase II prospective molecular profiling study in CUP	03/01/2018	13/09/2018		24/09/2018	01/10/2018		09/11/2018	Yes	N/A
109	18/EE/0191	228909	SMART filling for caries in primary teeth	30/01/2018	07/12/2018	06/12/2018		10/01/2019		22/01/2019	Yes	N/A
110	18/LO/1353	238135	Treatment of Urinary Retention with the Axonics SNM system / Version 1	20/07/2018	28/02/2019	09/01/2019		01/03/2019		14/03/2019	Yes	N/A

111	18/NW/0269	241839	Safety & Efficacy of Padsevonil in Subjects With DrugResistant Epilepsy	29/03/2019	01/05/2019	28/09/2018						N/A	N/A
112	19/LO/0359	253287	PK/PD of RO7234292 in CSF and plasma and safety and tolerability in HD	28/01/2019	17/06/2019	10/06/2019						N/A	N/A
113	19/LO/0309	259187	MS200647_0047 - M7824 in patients with metastatic biliary tract cancer	13/12/2018	19/06/2019	03/05/2019						N/A	N/A
114	18/LO/1922	251251	Study to Evaluate the Effect of GBT440 in Pediatrics with Sickle Cell	21/02/2019	21/02/2019	09/01/2019	12/03/2019	16/04/2019		23/04/2019	Yes	N/A	
115	19/LO/0051	251111	CINOVA	28/01/2019	19/06/2019	18/03/2019						N/A	N/A
116	17/NW/0634	209375	COMICE	05/09/2016	16/05/2019	16/01/2019	28/06/2019	28/06/2019				N/A	N/A
117	18/EE/0242	245484	Surrogate of Adequate Perfusion: Bladder tissue OXYgen monitoring	20/03/2018	28/03/2019	14/03/2019	26/03/2019	29/03/2019		05/04/2019	Yes	N/A	

Delivering Clinical Research

#	Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
1	40383	15/LO/0302	172756	Millennium C34001 Study	Number Agreed	4	4	Date Agreed	30/11/2016	4	13/07/2018	11	Recruitment Finished	
2	40385	15/SC/0666	187031	NEUR 4805	Number Agreed	10	10	Date Agreed	01/12/2017	10	24/10/2018	8	Recruitment Finished	
3	40387	16/LO/2157	217001	Retrophin	Number Agreed	4	4	Date Agreed	30/12/2017	4	07/09/2018	0	Withdrawn By Sponsor	
4	40391	14/SC/1366	135118	NCRN - 3131: EPOCH TheraSphere in Metastatic Colorectal Carcinoma of the Liver (TS102)	Number Agreed	6	6	Date Agreed	28/11/2016	6	01/09/2018	13	Recruitment Finished	
5	40401	14/LO/0566	145475	CANC - 3490 OLYMPIA	Number Agreed	3	3	Date Agreed	30/12/2018	3	31/12/2018	4	Recruitment Finished	
6	40402	15/NE/0167	171524	MLN9708 in Multiple Myeloma Not Treated with Stem Cell transplantation - MILLENIUM	Number Agreed	1	1	Date Agreed	30/07/2018	1	08/10/2018	0	Recruitment Finished	
7	40403	16/LO/0581	194313	CANC 5246	Not Available / Not Agreed			Not Available / Not Agreed			17/10/2018	5	Recruitment Finished	
8	40404	17/LO/0372	220433	REACH 2	Number Agreed	3	3	Not Available / Not Agreed			07/05/2019	1	Recruitment Finished	
9	40406	17/LO/1511	228836	Efficacy & safety of Olaparib in Castration-Resistant Prostate Cancer	Number Agreed	3	3	Date Agreed	30/06/2019	3	01/09/2018	0	Recruitment Finished	

10	40407	17/EE/0177	220722	BOSTON: Open-label Study of SVD versus VD in patients with RRMM	Number Agreed	3	3	Date Agreed	01/06/2020	3	10/04/2019	2	Recruitment Finished	
11	40408	15/LO/1079	177212	A safety and efficacy study of Multistem Cell Therapy for ARDS	Range Agreed	4	6	Date Agreed	26/11/2015	4	19/09/2018	4	Recruitment Finished	
12	40409	16/YH/0288	198946	TAI system in SCIs	Not Available / Not Agreed			Not Available / Not Agreed			30/09/2018	20	Recruitment Finished	
13	40410	16/NW/0305	201856	Ipsen223	Not Available / Not Agreed			Not Available / Not Agreed			03/10/2018	2	Withdrawn By Sponsor	Early closure from Sponsor
14	40411	16/EM/0324	204032	DEME 5472	Number Agreed	8	8	Date Agreed	09/11/2017	8	01/08/2018	2	Recruitment Finished	
15	40412	18/LO/0696	245087	Phase 2/3 Study of Arimoclomol in IBM	Number Agreed	50	50	Date Agreed	19/03/2019	50	19/03/2019	41	Recruitment Finished	
16	40413	17/EM/0183	220783	Effect of mepolizumab in severe bilateral nasal polyps	Number Agreed	4	4	Date Agreed	25/08/2017	4	15/11/2018	4	Recruitment Finished	
17	40414	17/LO/0797	220423	ABRE Study	Range Agreed	9	40	Date Agreed	30/12/2018	9	01/10/2018	9	Recruitment Finished	
18	40415	17/WA/0420	235469	IRL790C003 Phase IIA Parkinson's Dykinesia Study	Number Agreed	10	10	Date Agreed	31/08/2018	10	07/05/2019	4	Recruitment Finished	
19	40416	18/LO/0141	233922	OPINION, Olaparib Maintenance Monotherapy Ovarian Cancer.	Number Agreed	5	5	Date Agreed	30/03/2019	5	20/02/2019	2	Recruitment Finished	
20	40417	18/NW/0172	242180	STEP 1 - Semaglutide Treatment Effect in People with obesity	Number Agreed	20	20	Date Agreed	05/11/2018	20	31/10/2018	15	Withdrawn By Sponsor	
21	40418	15/LO/0008	163001	Intraprostatic PRX302 injection to treat localised prostate cancers	Number Agreed	20	20	Not Available / Not Agreed			28/11/2018	20	Recruitment Finished	
22	40419	16/LO/1874	213752	ACZ885 (canakinumab) in patients with sickle cell disease	Number Agreed	3	3	Date Agreed	25/03/2019	3	08/04/2019	13	Withdrawn By Sponsor	Recruitment currently on hold by sponsor.

23	40420	17/LO/1920	235022	Phase 3 Open-label with BIVV009 in Subjects with CAgD	Number Agreed	2	2	Date Agreed	30/12/2018	2	10/01/2019	2	Recruitment Finished
24	40421	16/LO/1755	209250	Revita-2	Number Agreed	15	15	Not Available / Not Agreed			09/11/2018	15	Withdrawn By Sponsor
25	40422	17/SC/0055	219468	AIN457 Paed	Number Agreed	2	2	Date Agreed	07/11/2018	2	28/09/2018	65	Recruitment Finished
26	40423	14/NE/1063	144094	GAST 3559 (Ulcerative Colitis)	Number Agreed	4	4	Date Agreed	30/12/2017	4	29/08/2018	1	Recruitment Finished
27	40424	14/NE/1099	144103	GAST 3772	Number Agreed	4	4	Date Agreed	30/12/2017	4	26/02/2019	0	Recruitment Finished